Whitepaper
8 Dec 2022

A stability indicating method for analysis of a complex drug product

PDF 911 kB

Find out how Recipharm developed a suitable analysis method for Lecigon® intestinal gel, a combination drug product containing three active pharmaceutical ingredients.

Content provided by our supplier

Recipharm AB

  • SE
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Contract Service
Manufacturer/Innovator

Other Content from Recipharm AB (26)

  • News Recipharm streamlines operations by selling oral solid dosage manufacturing site

    Astrea Pharma will be the new owner of the facility at Fontaine-lès-Dijon
  • Brochure Exploring new propellants

    Over the years, the prominence placed on creating a ‘greener’ future has increased dramatically. As a result, companies globally are facing growing pressure to adopt sustainable processes and reduce their carbon footprint. At Recipharm, we are taking a proactive approach to the situation and will be ready to adapt to any future changes of legislations, as well as supply challenges. 
  • News Watch now: Pharma Trends 2022 Webinar

    We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.
  • Technical Data Pilot plant

    nhalation development and manufacturing for early and late-stage clinical supply.

    Recipharm Inhalation Solutions™ offers comprehensive contract development and manufacturing solutions for early and late-phase clinical supply from our stand-alone pilot plant as part of our integrated inhalation offering.

  • News Lyophilisation technology improving thermal stability and reducing cycle times, says Recipharm expert

    Lyophilisation or freeze drying is an important means to improve thermal stability of a drug product, according to Thomas Becker, Quality Director and Qualified Person, Recipharm. This is particularly true for those that are thermolabile, such as mRNA vaccine candidates.

  • Sponsored Content How can we propel MDIs into a more sustainable future?

    Hydrofluoroalkane (HFAs), or F-gases, have been used as propellants in metered dose inhalers (MDIs) and other inhalation products for many years. However, due to their high global warming potential (GWP) – 1,430 times that of CO2, the United Nations (UN) has committed to reducing global HFA consumption by 80-85% by 2047, with the aim of slowing global warming (1).
  • Video Soft Mist Inhalers (SMIs) Based on Pre Filled Syringes

    Resyca, a joint venture between Recipharm and Medspray, is developing a novel type of soft mist inhaler devices, based on an existing primary packaging: glass pre filled syringes. This way we can utilise existing filling lines within Recipharm to do the aseptical filling. The lecture will describe the devices and the typical timelines for clinical and commercial supply.

    Most pharma and biological companies perform their drug discovery, pre clinical and phase 1 clinical work with nebulisers and liquid formulations. By using a soft mist inhaler device, they can take a shortcut and reach the market sooner and with lower development risks. Resyca's soft mist inhalers have been developed with biologics formulations in mind, being able to deliver milligrams of drug in a single inhalation from a pocket size device.


    Click here to register

  • Sponsored Content Key considerations to develop effective analytical methods for your drug project

    A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects.
  • Podcast CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner

    Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples. With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task. We speak with Frank Ternes, Chief Commercial Officer and Filip Ringborg, Director Contract Management & Operations Development, at Recipharm on best practice when it comes to selecting the right fit for your outsourcing requirements and how strategic partnerships built on trust are fundamental to success.
  • News CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner

    With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task.
  • Webinar CPHI Webinar Series Pharma Trend Outlook 2022

    As we approach the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event, we’re looking ahead to what 2022 has in store for the pharma industry. In this 60 minute, free-to-attend webinar, you’ll have the opportunity to hear from market experts from different sectors of the industry on the key trends, dynamics and disruptors we can anticipate in the coming year. Sourcing dynamics, the shift to self-administration, biotech innovation and sustainability are all high on the agenda – join us as we explore where the biggest opportunities and challenges lie and build your knowledge on where the industry is heading.
  • News Sterile manufacturing Annex 1 amendments: what, why and how explained

    In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.
  • Sponsored Content CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner

    Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples.
  • Sponsored Content Sterile manufacturing Annex 1 amendments: what, why and how explained

    In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update. 
  • News Recipharm expands its analytical services offering in India

    The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions
  • News Second Curaleaf GMP cannabis facility gains Spanish approval

    Medalchemy facility now fully licensed to import, cultivate, extract, manufacture and export medical cannabis flower and extracts
  • News Recipharm selected to operate new fill/finish facility in Morocco

    Move is part of US$500 million five-year investment programme by Moroccan government and consortium to establish vaccine and biotherapeutic manufacturing capacity in the country
  • News Resyca joint venture ready to push the boundaries of softmist technology

    Joint venture between Recipharm and Medspray could provide significant advantages for patients and the environment, companies say
  • News Top 5 Industry Content Reads on CPHI Online This Month

    If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

  • News Recipharm signs up for aseptic fill-finish manufacturing of Moderna COVID-19 vaccine

    The CDMO is already making certain investments to enable technology transfer and scale-up to commence imminently.
  • News Recipharm and Medspray establish joint venture to exploit novel softmist technology

    Resyca BV will provide a "unique offering" to the market — environmentally friendly, softmist spray nozzle technology for pharmaceutical applications.
  • News Recipharm invests in its pMDI valves production capacity

    The expansion will bolster the CDMO's offering by ensuring it can fulfil the forecasted increase in demand for respiratory devices.
  • News Recipharm’s proprietary molecule Erdosteine has been positively tested as part of COVID-19 treatment

    Recipharm is pleased to announce that the results of the study with Erdosteine as an add-on treatment for COVID-19 patients are now available.
  • News Recipharm to boost sterile liquids manufacturing capacity

    The investment will support increased demand and help to secure new business at its Kaysersberg facility.
  • News Recipharm invests EUR 2.6 million in Kaysersberg facility

    Global contract development and manufacturing organisation (CDMO), Recipharm, has announced a EUR 2.6 million investment for additional manufacturing capacity to support increased demand into its Kaysersberg facility.
  • News Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR[®]-COV19 (ARCT-021) vaccine candidate

    Recipharm, a leading contract development and manufacturing organisation (CDMO) has entered into an agreement with Arcturus Therapeutics, a leading U.S. based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.